High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease have?
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has 16 citations in the OpenAlex counts ScholarIQ stores.
When was High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease published?
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has 2018 year in the ScholarIQ index.
What is the open-access status of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has closed oa status in the ScholarIQ index.
What is the DOI of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?
The DOI for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.
What is the PMID of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?
The PMID for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.
What is the OpenAlex record for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?
The OpenAlex for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.